In: Journal of Antimicrobial Chemotherapy, 2017, vol. 72, no. 2, p. 376-384
|
In: Antimicrobial Agents and Chemotherapy, 2020, vol. 64, no. 2020-12, p. -
Metallo-β-lactamase (MBL)-producing Escherichia coli isolates resistant to the newly developed β-lactam/β-lactamase inhibitor drug combination aztreonam-avibactam (ATM-AVI) have been reported. Here, we analyzed a series of 118 clinical MBL- producing E. coli isolates of various geographical origins for susceptibility to ATM-AVI. The nature of the PBP3 protein sequence and the occurrence of...
|
In: Diagnostic Microbiology and Infectious Disease, 2020, vol. 97, no. 3, p. 115059
OXA-244 is a derivative of OXA-48 showing weaker carbapenemase activity, compromising the detection of corresponding producers in clinical laboratories. Since 2017, the Swiss National Reference Center for Emerging Antibiotic Resistance noticed an increased identification of OXA-244-producing Escherichia coli (n=15) within the country. Different methods (biochemical and immunoassay tests,...
|
In: Antimicrobial Agents and Chemotherapy, 2020, vol. 64, no. 4, p. -
Fosfomycin is gaining renewed interest for treating urinary tract infections. Monitoring fosfomycin resistance is therefore important in order to detect the emergence of novel resistance mechanisms. Here, we used the Rapid Fosfomycin NP test to screen a collection of extended-spectrum-β-lactamase- producing Escherichia coli isolates from Switzerland and found a fosfomycin- resistant isolate...
|
In: Journal of Antimicrobial Chemotherapy, 2019, vol. 74, no. 7, p. 1934–1939
To evaluate the efficacy of the recently launched β-lactam/β-lactamase inhibitor combinations ceftazidime/avibactam and ceftolozane/tazobactam against ESBL- producing Escherichia coli and Pseudomonas aeruginosa strains.Methods: A series of ESBL-encoding genes (blaTEM, blaSHV, blaCTX-M, blaVEB, blaPER, blaGES and blaBEL) was cloned and expressed in E. coli or P. aeruginosa recipient strains. ...
|
In: Applied Microbiology and Biotechnology, 2014, vol. 98, no. 10, p. 4445-4455
|
In: European Food Research and Technology, 2014, vol. 239, no. 1, p. 79-86
|
In: European Journal of Clinical Microbiology & Infectious Diseases, 2019, vol. 38, no. 5, p. 945–949
Our aim was to evaluate the prevalence of fosfomycin-resistant strains among ESBL- producing Escherichia coli isolates recovered from community patients in Switzerland. A total of 1225 ESBL-producing E. coli isolates were collected between 2012 and 2013 from a private and community laboratory. Fosfomycin resistance was assessed by using the novel rapid fosfomycin/E. coli NP test and agar...
|
In: Journal of Clinical Microbiology, 2019, vol. 57, no. 1, p. e01531-18
The rapid fosfomycin/Escherichia coli NP test was developed to detect fosfomycin resistance in E. coli isolates. The test is based on glucose metabolization and the detection of bacterial growth in the presence of fosfomycin at 40 µg/ml. Bacterial growth is visually detectable by an orange-to-yellow color change of red phenol, a pH indicator. A total of 100 E. coli isolates, among which 22...
|
In: Microbiology Spectrum, 2018, vol. 6, no. 4, p. -
Multidrug resistance in Escherichia coli has become a worrying issue that is increasingly observed in human but also in veterinary medicine worldwide. E. coli is intrinsically susceptible to almost all clinically relevant antimicrobial agents, but this bacterial species has a great capacity to accumulate resistance genes, mostly through horizontal gene transfer. The most problematic...
|